SEC Company Response from PURPLE BIOTECH LTD. (PPBT) (CIK 0001614744) (PPBT) — Nov 17, 2015

PURPLE BIOTECH LTD. (PPBT) (CIK 0001614744)
Date: Nov. 17, 2015 · CIK: 0001614744 · Accession: 0001144204-15-066514

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-207117

Date

November 17, 2015

Author

H.C. WAINWRIGHT & CO., LLC

Form

CORRESP

Company

PURPLE BIOTECH LTD. (PPBT) (CIK 0001614744)

Letter

Re: KITOV PHARMACEUTICALS HOLDINGS LTD.

November 17, 2015

VIA FACSIMILE AND EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

Registration Statement on Form F-1 (Registration No. 333-207117) -

Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright & Co., LLC (“Wainwright”), as representative of the underwriters for the referenced offering, hereby concurs in the request by Kitov Pharmaceuticals Holdings Ltd. that the effective date of the above-referenced registration statement be accelerated to 5:00 p.m. (Eastern Time), or as soon as practicable thereafter, on November 19, 2015, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.

Very truly yours,
H.C. WAINWRIGHT & CO., LLC

Show Raw Text

CORRESP
1
filename1.htm

November 17, 2015

VIA FACSIMILE AND EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

 Re: KITOV PHARMACEUTICALS HOLDINGS LTD.

  Registration Statement on Form F-1 (Registration No. 333-207117) -

  Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright &
Co., LLC (“Wainwright”), as representative of the underwriters for the referenced offering, hereby concurs in
the request by Kitov Pharmaceuticals Holdings Ltd. that the effective date of the above-referenced registration statement be accelerated
to 5:00 p.m. (Eastern Time), or as soon as practicable thereafter, on November 19, 2015, pursuant to Rule 461 under the Securities
Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.

    Very truly yours,

    H.C. WAINWRIGHT & CO., LLC

    By:
    /s/
    Mark W. Viklund

    Name: Mark W. Viklund

    Title: Chief Executive
    Officer

    430 Park Avenue | New York, New York 10022 | 212.356.0500

Security services provided by H.C. Wainwright & Co., LLC | Member: FINRA/SIPC

SecProbe.io